H. Lee Moffitt Cancer Center & Research Institute

Search Moffitt.org

Find an Investigator

Jin Q. Cheng, PhD, MD

Jin Q. Cheng, PhD, MD

Faculty Rank:

Senior Member

Titles:

Department/Program Affiliations:

  • Molecular Oncology

Primary Address:

H. Lee Moffitt Cancer Center &
Research Institute
12902 Magnolia Drive
Tampa, FL 33612

Office:

(813) 745-6915

USF Affiliations/College Department:

  • Medicine / Oncologic Sciences

University Academic Rank:

Professor

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Jin Q. Cheng, PhD, MD

Education & Training:

  • PhD, Paris University 13, 1994 - Molecular cell biology
  • MD, Beijing Medical School, 1986 - Medicine

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Jin Q. Cheng, PhD, MD

Research Interests:

A major interest of our laboratory is to study the genetic alterations and their molecular mechanisms in human ovarian and breast cancer. Specifically, we are interested in elucidation of normal cellular function of the PI3K/Akt and Aurora-A pathways and to characterize their role in human ovarian carcinogenesis. In particular, we are focusing on the identification of molecules that are specifically regulated by Akt or Aurora-A as well as the molecules that are regulated by PI3K/PTEN but not Akt. We are also interested in the identification of small molecule inhibitors of Akt and Aurora-A for cancer intervention. In addition, we are also working on the role of microRNA and a newly identified NGB tumor suppressor gene in human cancer.


Key word


Oncogene, tumor suppressor gene, signal transduction, drug discovery


Key words: Oncogene, signal transduction, growth factors, PKB/Akt, drug discovery.

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Jin Q. Cheng, PhD, MD

Publications:

  1. Guo JP, Shu SK, Esposito NN, Coppola D, Koomen JM, Cheng JQ. IKKepsilon phosphorylation of ERalpha-Ser167 and contribution to tamoxifen resistance in breast cancer. J Biol Chem. 2009 Nov;. Pubmedid: 19940156.   Pubmed ID: 19940156

  2. Guo JP, Shu SK, He L, Lee YC, Kruk PA, Grenman S, Nicosia SV, Mor G, Schell MJ, Coppola D, Cheng JQ. Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol. 2009 Jul;175(1):324-333. Pubmedid: 19497997.   Pubmed ID: 19497997

  3. Kayser-Bricker KJ, Glenn MP, Lee SH, Sebti SM, Cheng JQ, Hamilton AD. Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents. Bioorg Med Chem. 2009 Feb;17(4):1764-1771. Pubmedid: 19179081.   Pubmed ID: 19179081

  4. Kong W, Zhao JJ, He L, Cheng JQ. Strategies for profiling microRNA expression. J Cell Physiol. 2009 Jan;218(1):22-25. Pubmedid: 18767038.   Pubmed ID: 18767038

  5. Koren J, Jinwal UK, Jin Y, O'Leary J, Jones JR, Johnson AG, Blair LJ, Abisambra JF, Chang L, Miyata Y, Cheng AM, Guo J, Cheng JQ, Gestwicki JE, Dickey CA. Facilitating Akt clearance via manipulation of Hsp70 activity and levels. J Biol Chem. 2009 Nov;. Pubmedid: 19889640.   Pubmed ID: 19889640

  6. Mohapatra S, Chu B, Zhao X, Djeu J, Cheng JQ, Pledger WJ. Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors. Int J Biochem Cell Biol. 2009 Mar;41(3):595-602. Pubmedid: 18708158.   Pubmed ID: 18708158

  7. Park S, Guo J, Kim D, Cheng JQ. Identification of 24p3 as a direct target of FOXO3a that is regulated by IL3 through PI3K/Akt pathway. J Biol Chem. 2009 Jan;284(4):2187-2193. Pubmedid: 19056725.   Pubmed ID: 19056725

  8. Yuan Z, Kim D, Shu S, Wu J, Guo J, Xiao L, Kaneko S, Coppola D, Cheng JQ. Phosphoinositide 3-kinase/Akt inhibits MST1-mediated proapoptotic signaling through phosphorylation of threonine-120. J Biol Chem. 2009 Nov;. Pubmedid: 19940129.   Pubmed ID: 19940129

  9. Zhang Y, Zhang M, Dong H, Yong S, Li X, Olashaw N, Kruk PA, Cheng JQ, Bai W, Chen J, Nicosia SV, Zhang X. Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene. 2009 Jan;28(3):445-460. Pubmedid: 18850005.   Pubmed ID: 18850005

  10. Bermudez Y, Yang H, Cheng J, Kruk P. Pyk2/ERK 1/2 mediate Sp1- and c-Myc-dependent induction of telomerase activity by epidermal growth factor. Growth Factors. 2008 Feb;26(1):1-11. Pubmedid: 18365874.   Pubmed ID: 18365874

  11. Cheng G, Park S, Shu S, He L, Kong W, Zhang W, Yuan Z, Wang L, Cheng J. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets. 2008 Feb;8(1):2-6. Pubmedid: 18288938.   Pubmed ID: 18288938

  12. Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M, Xu LM, Costanzo C, Cheng JQ, Wang LH. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem. 2008 May;283(21):14665-14673. Pubmedid: 18353781.   Pubmed ID: 18353781

  13. Cheng J. Akt pathway in oncogenesis and anti-cancer therapy. Curr Cancer Drug Targets. 2008 Feb;8(1):1-1. Pubmedid: 18288937.   Pubmed ID: 18288937

  14. Dickey CA, Koren J, Zhang YJ, Xu YF, Jinwal UK, Birnbaum MJ, Monks B, Sun M, Cheng JQ, Patterson C, Bailey RM, Dunmore J, Soresh S, Leon C, Morgan D, Petrucelli L. Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A. 2008 Mar;105(9):3622-3627. Pubmedid: 18292230.   Pubmed ID: 18292230

  15. Garden AS, Harris J, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS, Ang KK. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys. 2008 Aug;71(5):1351-1355. Pubmedid: 18640496. Pmcid: PMC2582390.   Pubmed ID: 18640496

  16. He L, Yang H, Ma Y, Pledger WJ, Cress WD, Cheng JQ. Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression. J Biol Chem. 2008 Nov;283(45):31012-31020. Pubmedid: 18776222.   Pubmed ID: 18776222

  17. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ. MicroRNA-155 Is regulated by transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008 Nov;28(22):6773-6784. Pubmedid: 18794355.   Pubmed ID: 18794355

  18. Wang J, Cheng J. A simple method for profiling miRNA expression. Methods Mol Biol. 2008 414;414:183-190. Pubmedid: 18175820.   Pubmed ID: 18175820

  19. Yang H, Kong W, He L, Zhao J, O'Donnell J, Wang J, Wenham R, Coppola D, Kruk P, Nicosia S, Cheng J. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cellsurvival and cisplatin resistance by targeting PTEN. Cancer Res. 2008 Jan;68(2):425-433. Pubmedid: 18199536.   Pubmed ID: 18199536

  20. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008 Nov;283(45):31079-31086. Pubmedid: 18790736.   Pubmed ID: 18790736

  21. Bermudez Y, Yang H, Saunders B, Cheng J, Nicosia S, Kruk P. VEGF- and LPA-induced telomerase in human ovarian cancer cells is Sp1-dependent. Gynecol Oncol. 2007 Jun;106(3):526-37. Pubmedid: 17559911.   Pubmed ID: 17559911

  22. Ghosh N, Patel N, Jiang K, Watson J, Cheng J, Chalfant CE, Cooper DR. Ceramide-activated protein phosphatase (CAPP) involvement in insulin resistance via Akt, serine/arginine-rich protein 40, and ribonucleic acid splicing in L6 skeletal muscle cells. Endocrinology. 2007 Mar;148(3):1359-1366. Pubmedid: 17158207.   Pubmed ID: 17158207

  23. Kayser KJ, Glenn MP, Sebti SM, Cheng JQ, Hamilton AD. Modifications of the GSK3beta substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics. Bioorg Med Chem Lett. 2007 Apr;17(7):2068-73.. Pubmedid: 17276059.   Pubmed ID: 17276059

  24. Lee H, Kim D, Dan HC, Wu EL, Gritsko TM, Cao C, Nicosia SV, Golemis EA, Liu W, Coppola D, Brem SS, Testa JR, Cheng JQ. Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein. Mol Cell Biol. 2007 Mar;27(6): 2103-19. Pubmedid: 17210637.   Pubmed ID: 17210637

  25. Naidu K, Fang Q, Naidu K, Cheng J, Nicosia S, Coppola D. P53 enhances ascorbyl stearate-induced G2/M arrest of human ovarian cancer cells. Anticancer Res. 2007 Nov;27(6B):3927-3934. Pubmedid: 18225552.   Pubmed ID: 18225552

  26. Park J, Zheng W, Kim D, Cheng J, Kumar N, Ahmad N, Pow-Sang J. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev. 2007 Nov;31(5):359-365. Pubmedid: 18037591.   Pubmed ID: 18037591

  27. Ren Y, Chen Z, Chen L, Woods N, Reuther G, Cheng J, Wang H, Wu J. Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL. J Biol Chem. 2007 Dec;282(50):36463-36473. Pubmedid: 17942397.   Pubmed ID: 17942397

  28. Sagatys E, Garrett C, Boulware D, Kelley S, Malafa M, Cheng J, Sebti S, Coppola D. Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia. Hum Pathol. 2007 Oct;38(10):1526-31. Pubmedid: 17640711.   Pubmed ID: 17640711

  29. Saglam O, Garrett C, Boulware D, Sayegh Z, Shibata D, Malafa M, Yeatman T, Cheng J, Sebti S, Coppola D. Activation of the serine/threonine protein kinase AKT during the progression of colorectal neoplasia. Clin Colorectal Cancer. 2007 Sep;6(9):652-656. Pubmedid: 17945038.   Pubmed ID: 17945038

  30. Takahashi Y, Coppola D, Matsushita N, Cualing HD, Sun M, Sato Y, Liang C, JungJU, Cheng JQ, Mule JJ, Pledger WJ, Wang HG. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol. 2007 Oct;9(10):1142-1151. Pubmedid: 17891140.   Pubmed ID: 17891140

  31. Yang L, Sun M, Sun X, Cheng G, Nicosia S, Cheng J. Akt attenuation of the serine protease activity of HtrA2/Omi through phosphorylation of serine-212. J Biol Chem. 2007 Apr;282(15):10981-7. Pubmedid: 17311912.   Pubmed ID: 17311912

  32. Fang Q, Naidu K, Naidu K, Zhao H, Sun M, Dan H, Nasir A, Kaiser H, Cheng J, Nicosia S, Coppola D. Ascorbyl stearate inhibits cell proliferation and tumor growth in human ovarian carcinoma cells by targeting the PI3K/AKT pathway. Anticancer Res. 2006 Jan;26(1A):203-209. Pubmedid: 16475700.   Pubmed ID: 16475700

  33. Karst A, Dai D, Cheng J, Li G. Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival. Cancer Res. 2006 Oct;66(18):9221-9226. Pubmedid: 16982766.   Pubmed ID: 16982766

  34. Pu P, Kang C, Li J, Jiang H, Cheng J. The Effects of Antisense AKT2 RNA on the Inhibition of Malignant Glioma Cell Growth in vitro and in vivo. J Neurooncol. 2006 Jan;76(1):1-11. Pubmedid: 16402276.   Pubmed ID: 16402276

  35. Wang G, Barrett J, Stanford M, Werden S, Johnston J, Gao X, Sun M, Cheng J, McFadden G. Infection of human cancer cells with mxyoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A. 2006 Mar;103(12):4640-4645. Pubmedid: 16537421.   Pubmed ID: 16537421

  36. Yang H, He L, Kruk P, Nicosia S, Cheng J. Aurora-A induces cell survival and chemoresistance by activation of Akt througha p53-dependent manner in ovarian cancer cells. Int J Cancer. 2006 Nov;119(10):2304-2312. Pubmedid: 16894566.   Pubmed ID: 16894566

  37. Ang K, Harris J, Garden A, Trotti A, Jones C, Carrascosa L, Cheng J, Spencer S, Forastiere A, Weber R. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol. 2005 May;23(13):3008-3015. Pubmedid: 15860857.   Pubmed ID: 15860857

  38. Cheng J, Lindsley C, Cheng G, Yang H, Nicosia S. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene. 2005 Nov;24(50):7482-7492. Pubmedid: 16288295.   Pubmed ID: 16288295

  39. Kim D, Cheng G, Lindsley C, Yang H, Cheng J. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr Opin Investig Drugs. 2005 Dec;6(12):1250-1258. Pubmedid: 16370391.   Pubmed ID: 16370391

  40. Kim D, Dan H, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, Nicosia S, Cheng J. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci. 2005 Jan;10:975-987. Pubmedid: 15569636.   Pubmed ID: 15569636

  41. Nam S, Buettner R, Turkson J, Kim D, Cheng J, Muehlbeyer S, Hippe F, VatterS, Merz K, Eisenbrand G, Jove R. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A. 2005 Apr;102(17):5998-6003. Pubmedid: 15837920.   Pubmed ID: 15837920

  42. Nam S, Kim D, Cheng J, Zhang S, Lee J, Buettner R, Mirosevich J, Lee F, Jove R. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005 Oct;65(20):9185-9189. Pubmedid: 16230377.   Pubmed ID: 16230377

  43. Niesen M, Osborne A, Yang H, Rastogi S, Chellappan S, Cheng J, Boss J, Blanck G. Activation of a methylated promoter mediated by a sequence-specific DNA-binding protein, RFX. J Biol Chem. 2005 Oct;280(47):38914-38922. Pubmedid: 16166088.   Pubmed ID: 16166088

  44. Park S, Kim D, Kaneko S, Szewczyk K, Nicosia S, Yu H, Jove R, Cheng J. Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway. J Biol Chem. 2005 Nov;280(47):38932-38941. Pubmedid: 16174774.   Pubmed ID: 16174774

  45. Patel N, Kaneko S, Apostolatos H, Bae S, Watson J, Davidowitz K, Chappell D, Birnbaum M, Cheng J, Cooper D. Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CbetaII alternative splicing via phosphorylation of serine/arginine-richsplicing factor SRp40. J Biol Chem. 2005 Apr;280(14):14302-14309. Pubmedid: 15684423.   Pubmed ID: 15684423

  46. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza G, Cheng J, Jove R, Yu H. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005 Aug;24(36):5552-5560. Pubmedid: 16007214.   Pubmed ID: 16007214

  47. Yang H, Zheng S, Meijer L, Li S, Leclerc S, Yu L, Cheng J, Zhang S. Screening the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34(cdc2) kinase. J Zhejiang Univ Sci. 2005 Jul;6B:656-663. Pubmedid: 15973768.   Pubmed ID: 15973768

  48. Yuan Z, Kim D, Kaneko S, Sussman M, Bokoch G, Kruh G, Nicosia S, Testa JR, Cheng J. ArgBP2gamma interacts with Akt and p21-activated kinase-1 and promotes cell survival. J Biol Chem. 2005 Jun;280(22):21483-21490. Pubmedid: 15784622.   Pubmed ID: 15784622

  49. Dan H, Jiang K, Coppola D, Hamilton A, Nicosia S, Sebti S, Cheng J. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene. 2004;23(3):706-715. Pubmedid: 14737105.   Pubmed ID: 14737105

  50. Dan H, Sun M, Kaneko S, Feldman R, Nicosia S, Wang H, Tsang B, Cheng JQ. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem. 2004;279(7):5405-5412. Pubmedid: 14645242.   Pubmed ID: 14645242

  51. Jiang K, Sun J, Cheng J, Djeu J, Wei S, Sebti S. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol. 2004;24(12):5565-5576. Pubmedid: 15169915.   Pubmed ID: 15169915

  52. Johnson N, Dan H, Cheng J, Kruk P. BRCA1 185delAG mutation inhibits Akt-dependent, IAP-mediated caspase 3 inactivation in human ovarian surface epithelial cells. Exp Cell Res. 2004;298:9-16. Pubmedid: 15242757.   Pubmed ID: 15242757

  53. Liu Q, Kaneko S, Yang L, Feldman R, Nicosia S, Chen J, Cheng J. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem. 2004;279(50):52175-52182. Pubmedid: 15469940.   Pubmed ID: 15469940

  54. Nicosia S, Wilbanks G, Saunders B, Mayer J, Cardosi R, Kruk P, Cheng J, Bai W, Coppola D, Fiorica J. Cytology of human ovarian surface epithelial brushings. Cancer Cytopathol. 2004;102(1):1-10. Pubmedid: 14968412.   Pubmed ID: 14968412

  55. Stahl J, Sharma A, Cheung M, Zimmerman M, Cheng J, Bosenberg M, KesterM, Sandirasegarane L, Robertson G. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004;64(19):7002-7010. Pubmedid: 15466193.   Pubmed ID: 15466193

  56. Yang H, Ou C, Feldman R, Nicosia S, Kruk P, Cheng J. Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res. 2004;64(2):463-467. Pubmedid: 14744757.   Pubmed ID: 14744757

  57. Yang L, Dan H, Sun M, Liu Q, Sun X, Feldman R, Hamilton A, Polokoff M, Nicosia S, Herlyn M, Sebti S, Cheng J. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004;64(13):4394-4399. Pubmedid: 15231645.   Pubmed ID: 15231645

  58. Chen T, Yang I, Irby R, Shain K, Wang H, Quackenbush J, Coppola D, Cheng JQ, Yeatman T. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Res. 2003;63(15):4368-4374. Pubmedid: 12907606.   Pubmed ID: 12907606

  59. Gritsko T, Coppola D, Paciga J, Yang L, Sun M, Shelley S, Fiorica J, Nicosia S, Cheng J. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res. 2003;9(4):1420-1426. Pubmedid: 12684414.   Pubmed ID: 12684414

  60. Iravani S, Zhang H, Yuan Z, Cheng J, Karl R, Jove R, Coppola D. Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia. Hum Pathol. 2003;34(10):975-982. Pubmedid: 14608530.   Pubmed ID: 14608530

  61. Nicosia S, Bai W, Cheng J, Coppola D, Kruk P. Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am. 2003;17(4):927-943. Pubmedid: 12959183.   Pubmed ID: 12959183

  62. Sekharam M, Zhao H, Sun M, Fang Q, Zhang Q, Yuan Z, Dan H, Boulware D, Cheng J, Coppola D. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res. 2003;63(22):7708-7716. Pubmedid: 14633695.   Pubmed ID: 14633695

  63. Sun M, Yang L, Feldman R, Sun X, Bhalla K, Jove R, Nicosia S, Cheng J. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem. 2003;278(44):42992-43000. Pubmedid: 12933816.   Pubmed ID: 12933816

  64. Yuan Z, Feldman R, Sussman G, Coppola D, Nicosia S, Cheng J. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation byphosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem. 2003;278(26):23432-23440. Pubmedid: 12697749.   Pubmed ID: 12697749

  65. Alfonso-De Matte M, Yang H, Evans M, Cheng J, Kruk P. Telomerase is regulated by c-Jun NH2-terminal kinase in ovarian surface epithelial cells. Cancer Res. 2002;62(16):4575-4578. Pubmedid: 12183409.   Pubmed ID: 12183409

  66. Cheng J, Jiang X, Fraser M, Li M, Dan H, Sun M, Tsang B. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat. 2002;5(3-4):131-146. Pubmedid: 12237081.   Pubmed ID: 12237081

  67. Dan H, Sun M, Yang L, Feldman R, Sui X, Ou C, Nellist M, Yeung R, Halley D, Nicosia S, Pledger W, Cheng J. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem. 2002;277(38):35364-35370. Pubmedid: 12167664.   Pubmed ID: 12167664

  68. Fox P, Cheng J, Lu J. Fourier-Bessel field calculation and tuning of a CW annular array. Ieee Trans Ultrason Ferroelectr Freq Control. 2002;49:1179-1190. Pubmedid: 12243569.   Pubmed ID: 12243569

  69. Kaneko S, Feldman R, Yu L, Wu Z, Gritsko T, Shelley S, Nicosia S, NoboriT, Cheng J. Positive feedback regulation between Akt2 and MyoD during muscle differentiation. Cloning of Akt2 promoter. J Biol Chem. 2002;277(26):23230-23235. Pubmedid: 11948187.   Pubmed ID: 11948187

  70. Li K, Wang L, Cheng J, Lu Y, Zhang L, Mou J, Hong Y, Liu Y, Duan H, Wang G, Li L, Chen J. [Mutual interaction between hepatitis C virus core protein and translin, arecombination hotspot binding protein] Chinese. Zhonghua Yi Xua Za Zhi. 2002;82:673-677. Pubmedid: 12133464.   Pubmed ID: 12133464

  71. Yuan Z, Feldman R, Sun M, Olashaw N, Coppola D, Sussmann G, Shelley S, Nicosia S, Cheng J. Inhibition of JNK by cellular stress- and tumor necrosis factor alpha-induced AKT2 through activation of the NF kappa B pathway in human epithelial cells. J Biol Chem. 2002;277(33):29973-29982. Pubmedid: 12048203.   Pubmed ID: 12048203

  72. Alfonso-De Matte M, Cheng J, Kruk P. Ultraviolet irradiation- and dimethyl sulfoxide-induced telomerase activity in ovarian epithelial cell lines. Exp Cell Res. 2001;267(1):13-27. Pubmedid: 11412034.   Pubmed ID: 11412034

  73. Sun M, Paciga J, Feldman R, Yuan Z, Shelley S, Nicosia S, Cheng J, Coppola D, Lu Y. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res. 2001;61(16):5985-5991. Pubmedid: 11507039.   Pubmed ID: 11507039

  74. Sun M, Wang G, Paciga J, Feldman R, Yuan Z, Ma X, Shelley S, Jove R, Tsichlis P, Nicosia S, Cheng J. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol. 2001;159(2):431-437. Pubmedid: 11485901.   Pubmed ID: 11485901

  75. Jiang K, Coppola D, Crespo N, Hamilton A, Nicosia S, Sebti S, Cheng J. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol. 2000;20(1):139-148. Pubmedid: 10594016.   Pubmed ID: 10594016

  76. Yuan Z, Sun M, Feldman R, Wang G, Ma X, Jiang C, Coppola D, Nicosia S, Cheng J. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 2000;19(19):2324-2330. Pubmedid: 10822383.   Pubmed ID: 10822383

  77. Cheng J, Lee W, Klein M, Cheng G, Jhanwar S, Testa J. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosom Cancer. 1999;24(3):238-242. Pubmedid: 10451704.   Pubmed ID: 10451704

  78. Kubo A, Nakagawa K, Varma R, Conrad N, Cheng J, Lee W, Testa J, Johnson B, Kaye F, Kelley M. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999;5(12):4279-4286. Pubmedid: 10632371.   Pubmed ID: 10632371

  79. Altomare D, Lyons G, Mitsuuchi Y, Cheng J, Testa J. Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin. Oncogene. 1998;16(18):2407-2411. Pubmedid: 9620559.   Pubmed ID: 9620559

  80. Cheng J, Jiang W, Hackney D. Interaction of mant-adenosine nucleotides and magnesium with kinesin. Biochem J. 1998;37(15):5288-5295. Pubmedid: 9548760.   Pubmed ID: 9548760

  81. Liu A, Testa J, Hamilton T, Jove R, Nicosia S, Cheng J. AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res. 1998;58(14):2973-2977. Pubmedid: 9679957.   Pubmed ID: 9679957

  82. Ruggeri B, Huang L, Wood M, Cheng J, Testa J. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinoma. Mol Carcinog. 1998;21:81-86. Pubmedid: 9496907.   Pubmed ID: 9496907

  83. Ruggeri B, Huang L, Wood M, Cheng J, Testa J. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog. 1998;211(2):81-86. Pubmedid: noPMID.  

  84. Cheng J, Altomare D, Klein W, Lee W, Kruh G, Lissy N, Testa J. Transforming activity and mitosis-dependent expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene. 1997;14:2793-2801. Pubmedid: 9190895.   Pubmed ID: 9190895

  85. Testa J, Liu Z, Feder M, Bell D, Balsara B, Cheng J, Taguchi T. Advances in the analysis of chromosome alterations in human lung carcinomas. Cancer Genet Cytogenet. 1997;95:20-32. Pubmedid: 9140450.   Pubmed ID: 9140450

  86. Cheng J, Ruggeri B, Klein W, Sonoda G, Altomare D, Watson D, Testa J. Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A. 1996;93:3636-3641. Pubmedid: 8622988.   Pubmed ID: 8622988

Jin Q. Cheng, PhD, MD

Below is a list of active grants where the faculty member is the Principal Investigator. Grants are sorted by sponsor and then sorted by start date, with the more recent grant shown first.

microRNA expression Signature in Human Melanomas
Sponsor: Moffitt Fdtn
Project Dates: September 1, 2009 to August 31, 2010
Earned to Date: $194,500

microRNA expression Signature in Human Melanomas
Sponsor: Moffitt Fdtn
Project Dates: September 1, 2009 to August 31, 2010
Earned to Date: $194,500

microRNA expression Signature in Human Melanomas
Sponsor: Moffitt Fdtn
Project Dates: September 1, 2009 to August 31, 2010
Earned to Date: $194,500

Haplotype-Based Genome Screen for Ovarian Cancer Loci

3 R01 CA114343-03S1
Sponsor: Nat Institutes of Health / NCI
Project Dates: September 30, 2009 to September 29, 2011
Earned to Date: $334,000

MicroRNAs in Human Ovarian Cancer

1 R01 CA137041-01A1
Sponsor: Nat Institutes of Health / NCI
Project Dates: June 1, 2009 to April 30, 2014
Annual Direct Cost: $207,500
Annual Total Cost: $346,352
Project Total: $1,732,452

Disruption of AKT Pathway for Cancer Intervention (NO COST EXTENSION)

5 R01 CA107078-06
Sponsor: Nat Institutes of Health / NCI
Project Dates: December 11, 2007 to May 31, 2010

MicroRNA's regulated by TGFbeta-dependent and -independent Pathways in Breast Cancer-initiating Cell and Metastasis

09BB-05
Sponsor: State of Florida / Dept of Health
Project Dates: July 1, 2009 to June 30, 2010
Earned to Date: $137,500

Molecular Signatures for Colon Cancer

08BR-02
Sponsor: State of Florida / Dept of Health
Project Dates: July 1, 2008 to June 30, 2011
Annual Direct Cost: $270,455
Annual Total Cost: $297,500
Project Total: $970,000

Functional Elucidation of Aberrant MicroRNA Expression in Oral Cancer

UF09080
Sponsor: Univ of Florida
Project Dates: June 11, 2009 to June 10, 2010
Earned to Date: $50,000

miRNA-based Strategies to Personalize Care for Women with Ovarian Cancer
Sponsor: Univ of South Florida
Project Dates: August 1, 2009 to July 31, 2010
Earned to Date: $75,000

miRNA-based Strategies to Personalize Care for Women with Ovarian Cancer Chemotherapy
Sponsor: Univ of South Florida
Project Dates: August 1, 2009 to July 31, 2010
Earned to Date: $36,237

MicroRNA's as Markers and Pathogenic Factors in Ovarian Cancer

W81XWH-08-2-0101
Sponsor: US Army
Project Dates: August 26, 2009 to July 31, 2010
Earned to Date: $123,824

The Role of miRNA's in Chemoresistance of Ovarian Carcinoma

OC073222
Sponsor: US Army
Project Dates: June 1, 2008 to December 31, 2009
Earned to Date: $124,500

Investigator  Contact Form

© Copyright 1996 - 2009 H. Lee Moffitt Cancer Center & Research Institute